Please Wait.....
Report
Nasal Vaccines: Global Markets and Pipeline Analysis
Market Research Report I 2022-12-28 I 78 Pages I BCC Research
Description
Report Scope:
This report examines trends and sales in the global market for nasal vaccines through 2027. Leaders in the industry and their vaccine portfolios, the need for nasal vaccine development, competitive intelligence and regional trends are discussed. The report includes a PESTEL analysis, that forms in part the base data for qualitative analysis and market estimates.
The report examines all forms of nasal vaccines, such as nasal drops or sprays, but excludes intramuscular and oral vaccines. The report discusses nasal vaccines by type, such as live-attenuated, inactivated, protein subunit and viral vectors. The application areas covered include pediatric and adult. Primary care clinics, hospitals, pharmacies and others are the end-user segments covered.
Report Includes:
- 23 data tables and 27 additional tables
- A comprehensive overview and up-to-date analysis of the global market for nasal vaccines
- Analyses of the global market trends, with historic market revenue data (sales figures) for 2019-2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
- Highlights of the upcoming market opportunities and trends driving and restricting growth of the global nasal vaccines market and its sub-segments, and the major regions and countries involved in market developments
- Estimation of the actual market size and revenue forecast for the global nasal vaccines market in USD millions, and its corresponding market share analysis by vaccine type, dosage form, patient group, end-user, and region
- Discussion of new developments in the nasal vaccines market, underlying clinical trials for all phases and list of vaccines, and their regulatory approvals etc.
- Identification of the major stakeholders and analysis of the competitive landscape based on recent developments, financial performance, and segmental revenues
- Review of the new announcements, approvals, FDA clearances, partnerships and collaborations in the global nasal vaccines market
- Detailed company profiles of the leading industry players, including AstraZeneca plc, BioDiem Ltd., BlueWillow Biologics, Meissa Vaccines Inc., and Serum Institute of India Pvt., Ltd.
Executive Summary
Summary:
In the wake of the COVID-19 pandemic, Nasal vaccines are experiencing increased demand. Leading manufacturers in the vaccine industry are eyeing nasal vaccines as future revenue producers. This can be attributed to increasing government and regulatory support, which has also led to the rapid development of effective intramuscular COVID vaccines. The emergence of coronavirus variants that can evade the immune response generated by existing vaccines has encouraged the research community and vaccine manufacturers to develop nasal vaccines that can be delivered as spray or drops into the nose and provide additional protection by stimulating mucosal immunity.
Nasal vaccines are anticipated to be a major game changer in blocking the transmission of diseases such as COVID-19. For instance, Indian vaccine manufacturer Bharat Biotech's intranasally administered COVID vaccine ais in Phase 3 clinical trials. The vaccine also received emergency use authorization (EUA) by the Indian Drug Authority in September 2022. AstraZeneca's nasal spray flu vaccine is used globally in children and adults. In Russia, the Gamaleya institute has developed the Sputnik nasal vaccine for adults and is currently being tested on children between the ages of 8 and 12, and so far, has shown no side effects.
Nasal vaccines have certain advantages over the mainstay vaccines. In the present situation of waning and waxing COVID waves due to new variants, the medical profession needs noninvasive and less expensive alternatives to injectable vaccines. Nasal vaccines achieve both: They eliminate the use of needles, thus reducing the cost of vaccines and facilitating mass vaccination. They also may increase vaccination compliance among individuals who are afraid of syringes. Because they can be delivered in spray form, nasal vaccines avoid the possibility of needle contamination. They are more cost-effective for low- and middle-income countries because the storage conditions required for these vaccines are
less complicated than the cold storage facilities required for intramuscular vaccines. Moreover, nasal vaccines are more effective against respiratory viruses, as they induce antibody production in the airway passages. Finally, nasal vaccines can be self-administered, relieving some of the pressure on overworked healthcare professionals. For viruses such as SARS-CoV-2 that can mutate rapidly, nasal vaccines are the best option as their spike proteins can be easily replaced to combat new versions of a virus.
The coordination between researchers, industrial resources, government support and conducive market forces will further propel the nasal vaccine market in the coming years. Researchers are optimistic about developing nasal vaccines to control the spread of the next pandemic, whether from COVID or another respiratory virus. This would be unlike coronavirus vaccines, where it is difficult to identify the vaccinated asymptomatic carriers and therefore cannot block the virus transmission chain. However, the market is in dire need of the substantial funding required to accelerate the development of nasal vaccines.
Table of Contents
Chapter 1 Introduction
1.1 Study Goals and Objectives
1.2 Reasons for Doing this Study
1.3 Scope of Report
1.4 Information Sources
1.5 Methodology
1.6 Geographic Breakdown
1.7 Analyst's Credentials
1.8 BCC Custom Research
1.9 Related BCC Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Market Overview
3.1 Nasal Immune Response
3.2 Benefits of Developing Nasal Vaccines
3.3 Market Drivers
3.3.1 Rising Incidence of Respiratory Infections
3.3.2 Cost-Effective Alternative to Mainstream Vaccines
3.3.3 Increased Government Support and Favorable Regulations
3.3.4 Rising Awareness of the Need for Vaccination Programs
3.3.5 R&D for Nasal Vaccines
3.4 Market Restraints
3.4.1 Limited Immunization in Low- and Middle-Income Countries
3.4.2 Technical Drawbacks of Nasal Vaccines
3.5 Market Opportunities
3.5.1 Demand for Innovative Approaches to Combat COVID-19
3.6 PESTEL Analysis
3.7 Reimbursement Scenarios
3.8 Impact of COVID-19 on the Market for Nasal Vaccines
Chapter 4 Pipeline Analysis of Nasal Vaccines
4.1 Nasal Vaccine Product Pipeline
4.1.1 Product Pipeline, by Clinical Trial Phase
4.1.2 Product Pipeline, by Disease
4.1.3 Product Pipeline, by Vaccine Type
Chapter 5 Global Market for Nasal Vaccines by Type
5.1 Live-Attenuated Vaccines
5.2 Inactivated Vaccines
5.3 Viral Vector Vaccines
5.4 Protein Subunit Vaccines
Chapter 6 Global Market for Nasal Vaccines by Dosage Form
6.1 Nasal Sprays
6.2 Nasal Drops
6.3 Nasal Powders
6.4 Nasal Gels
Chapter 7 Global Market for Nasal Vaccines by Patient Group
7.1 Pediatric
7.2 Adult
Chapter 8 Global Market for Nasal Vaccines by End User
8.1 Primary Care Clinics
8.2 Hospitals
8.3 Pharmacies
8.4 Other End Users
Chapter 9 Global Market for Nasal Vaccines by Region
9.1 North America
9.2 Europe
9.3 Asia-Pacific
9.4 Rest of the World (RoW)
Chapter 10 Competitive Landscape
10.1 Announcements
10.2 Drug Approvals
10.3 Partnerships and Collaborations
Chapter 11 Company Profiles
ASTRAZENECA PLC
BHARAT BIOTECH INTERNATIONAL LTD.
BIODIEM LTD.
BLUEWILLOW BIOLOGICS INC.
CODAGENIX INC.
CHANGCHUN BCHT BIOTECHNOLOGY CO.
CYANVAC LLC
INTRAVACC LLC
MEISSA VACCINES INC.
RAZI VACCINE AND SERUM RESEARCH INSTITUTE
SERUM INSTITUTE OF INDIA PVT. LTD.
List of Tables
Summary Table : Global Market for Nasal Vaccines, by Region, Through 2027
Table 1 : Impact Analysis of Market Drivers and Restraints
Table 2 : Confirmed Cases of COVID-19, by Region, as of September 27, 2022
Table 3 : Global Nasal Vaccine Product Pipeline, 2019-2022
Table 4 : Global Market for Live-Attenuated Nasal Vaccines, by Region, Through 2027
Table 5 : Global Market for Nasal Spray Vaccines, by Region, Through 2027
Table 6 : Global Market for Nasal Vaccines, by Patient Group, Through 2027
Table 7 : Global Market for Pediatric Nasal Vaccines, by Region, Through 2027
Table 8 : Global Market for Adult Nasal Vaccines, by Region, Through 2027
Table 9 : Global Market for Nasal Vaccines, by End User, Through 2027
Table 10 : Global Market for Nasal Vaccines in Primary Care Clinics, by Region, Through 2027
Table 11 : Global Market for Nasal Vaccines in Hospitals, by Region, Through 2027
Table 12 : Global Market for Nasal Vaccines in Pharmacies, by Region, Through 2027
Table 13 : Global Market for Nasal Vaccines for Other End Users, by Region, Through 2027
Table 14 : North American Market for Nasal Vaccines, by Patient Group, Through 2027
Table 15 : North American Market for Nasal Vaccines, by End User, Through 2027
Table 16 : European Market for Nasal Vaccines, by Patient Group, Through 2027
Table 17 : European Market for Nasal Vaccines, by End User, Through 2027
Table 18 : Asia-Pacific Market for Nasal Vaccines, by Patient Group, Through 2027
Table 19 : Asia-Pacific Market for Nasal Vaccines, by End User, Through 2027
Table 20 : Rest of the World Market for Nasal Vaccines, by Patient Group, Through 2027
Table 21 : Rest of the World Market for Nasal Vaccines, by End User, Through 2027
Table 22 : Announcements in the Global Nasal Vaccines Market, 2020-2022
Table 23 : Recent Drug Approvals in the Global Nasal Vaccines Market, 2021-2022
Table 24 : Partnerships and Collaborations in the Global Nasal Vaccines Market, 2020-2021
Table 25 : AstraZeneca: Vaccine Portfolio
Table 26 : AstraZeneca: Financial Performance, 2019-2021
Table 27 : AstraZeneca: Recent Developments, 2022
Table 28 : Bharat Biotech: Vaccine Portfolio
Table 29 : Bharat Biotech: Recent Developments, 2022
Table 30 : BioDiem Ltd.: Vaccine Portfolio
Table 31 : BioDiem Ltd.: Financial Performance, 2019-2021
Table 32 : BioDiem Ltd.: Recent Developments, 2020-2021
Table 33 : BlueWillow Biologics Inc.: Vaccine Development Programs
Table 34 : BlueWillow Biologics Inc.: Recent Developments, 2019-2022
Table 35 : Codagenix Inc.: Vaccine Portfolio
Table 36 : Codagenix Inc.: Recent Developments, 2020-2022
Table 37 : BCHT: Vaccine Portfolio
Table 38 : BCHT: Recent Developments, 2021
Table 39 : CyanVac LLC: Vaccine Portfolio
Table 40 : CyanVac LLC: Recent Developments, 2021-2022
Table 41 : Intravacc LLC: Vaccine Portfolio
Table 42 : Intravacc LLC: Financial Performance, 2019-2021
Table 43 : Intravacc: Recent Developments, 2022
Table 44 : Meissa Vaccines Inc.: Vaccine Portfolio
Table 45 : Meissa Vaccines Inc.: Recent Developments, 2020-2022
Table 46 : Razi Vaccines: Vaccine Portfolio
Table 47 : Razi Vaccines: Recent Developments, 2021
Table 48 : Serum Institute of India: Vaccine Portfolio
Table 49 : Serum Institute of India: Recent Developments, 2020-2021
List of Figures
Summary Figure A : Global Market for Nasal Vaccines, by Region, 2022 and 2027
Summary Figure B : Pipeline Analysis of Nasal Vaccines, by Clinical Trial Phase, 2019-2022
Figure 1 : PESTEL Analysis of the Nasal Vaccine Market
Figure 2 : Distribution Share of Nasal Vaccine Product Pipeline, by Clinical Trial Phase, 2019-2022
Figure 3 : Distribution Share of Nasal Vaccine Product Pipeline, by Disease, 2019-2022
Figure 4 : Distribution Share of Nasal Vaccine Product Pipeline, by Vaccine Type, 2019-2022
Figure 5 : Global Market Shares of Live-Attenuated Nasal Vaccines, by Region, 2022
Figure 6 : Global Market for Live-Attenuated Nasal Vaccines, 2019-2027
Figure 7 : Global Market Shares of Nasal Spray Vaccines, by Region, 2022 and 2027
Figure 8 : Global Market Shares of Nasal Vaccines, by Patient Group, 2022
Figure 9 : Global Market for Nasal Vaccines, by End User, 2022 and 2027
Figure 10 : Snapshot of the Global Market Shares of Nasal Vaccines, by Region, 2022
Figure 11 : North American Market for Nasal Vaccines, 2019-2027
Figure 12 : European Market for Nasal Vaccines, 2019-2027
Figure 13 : Asia-Pacific Market for Nasal Vaccines, 2019-2027
Figure 14 : Rest of the World Market for Nasal Vaccines, 2019-2027
Figure 15 : Global Market Shares of Nasal Vaccines, by Key Strategies Adopted, 2020-2022
Figure 16 : AstraZeneca: Annual Revenue, 2019-2021
Figure 17 : AstraZeneca: Total Sales Share, by Segment, 2021
Figure 18 : AstraZeneca: Total Revenue Share, by Region, 2021
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security